This activity was originally presented at the 2025 HOPA Annual Conference in Portland, Oregon.
Program Description
Bispecific antibodies (BsAbs) have significantly expanded treatment options for relapsed/refractory lymphomas. With several new approvals, oncology pharmacists play a crucial role in integrating BsAbs into patient care, including appropriate onboarding and operational strategies, managing formulary inclusion, and educating health care teams about complex adverse effects associated with BsAbs. This session will explore the evolving landscape of BsAb therapy, covering key aspects of these novel therapies, including their pharmacology, clinical evidence, and emerging indications. Interactive case-based discussions will engage participants in real-world scenarios, addressing treatment selection challenges, strategies for managing toxicities like cytokine release syndrome (CRS), and best practices for interdisciplinary communication and guideline development.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 17, 2025
Expiration date: April 17, 2026
Time to complete activity: 1.0 hours
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine updates in efficacy and safety data for bispecific antibodies (BsAbs) in follicular and diffuse large B-cell lymphoma
- Construct comprehensive care plans for BsAb therapy that prioritize patient education, proactive toxicity prophylaxis, and effective monitoring and management strategies
- Provide collaborative strategies to optimize BsAb utilization in community practices, leveraging knowledge and resources from academic health care providers
Emilie Aschenbrenner, PharmD, BCOP
Hematology Pharmacy Coordinator
Clinical Oncology Pharmacist
Froedtert & the Medical College of Wisconsin
Wauwatosa, Wisconsin
Joseph G. Bennett, MD
Chief Fellow
Rising Assistant Professor
Department of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center
Kansas City, Kansas
Joseph A. Kalis, PharmD, BCOP
Ambulatory Oncology Pharmacist, Hematology/Oncology
UCHealth
Colorado Springs, Colorado
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-25-109-H01-P. The activity is available for CE credit through April 17, 2026.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Emilie Aschenbrenner, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Genmab, Amgen, Sanofi
Speakers Bureau: AbbVie, Incyte, Sanofi, BeiGene, BMS, Astellas
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Joseph G. Bennett, MD and Joseph A. Kalis, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms